McKesson recorded a pre-tax charge of $8.1 billion related to opioid litigation, resulting in third quarter Loss per diluted share of ($39.03)

McKesson Corporation (NYSE:MCK) reported results for the third quarter ended December 31, 2020.

Third-quarter Loss per diluted share of ($39.03) included a pre-tax $8.1 billion expense accrual related to opioid litigation and a pre-tax long-lived asset impairment charge of $115 million primarily related to McKesson’s retail pharmacy businesses in the International segment. Third-quarter Adjusted Earnings per diluted share does not include these charges.


Download PDF File from here.